CNSP Narrows Q3 Loss Amidst Aggressive Equity Raises

TL;DR

**CNSP is burning cash and relying on constant stock sales to stay afloat, making it a high-risk bet on future drug success.**

AI Summary

CNS Pharmaceuticals, Inc. (CNSP) reported a net loss of $9,894,762 for the nine months ended September 30, 2025, an improvement from the $11,681,435 net loss in the same period of 2024. This 15.3% reduction in net loss was primarily driven by decreased operating expenses, with general and administrative costs falling from $3,909,928 to $3,393,655 and research and development expenses decreasing from $7,791,967 to $6,606,778. The company's cash and cash equivalents significantly increased to $9,864,087 as of September 30, 2025, up from $6,461,378 at December 31, 2024, largely due to $13,544,685 in proceeds from the sale of common stock and warrants. Despite these financing activities, CNSP continues to operate at a net loss and negative cash flows from operations, raising substantial doubt about its ability to continue as a going concern, as explicitly stated in Note 2 of the filing. The company executed multiple reverse stock splits, including a 1-for-12 split on July 22, 2025, to manage its share structure.

Why It Matters

For investors, CNSP's continued reliance on equity financing, evidenced by $13.5 million in proceeds from stock and warrant sales, is a critical signal of its cash burn and lack of sustainable revenue. The repeated reverse stock splits (three since June 2024, including a 1-for-12 split in July 2025) are often a red flag, indicating efforts to maintain NASDAQ listing compliance rather than fundamental business strength, potentially diluting long-term shareholder value. Employees face uncertainty given the 'going concern' warning, while customers and the broader market for anti-cancer drugs await clinical breakthroughs that justify the company's significant R&D spend. Competitively, CNSP's ability to advance its drug candidates is directly tied to its financing success, placing it in a precarious position against better-capitalized pharmaceutical firms.

Risk Assessment

Risk Level: high — The company explicitly states in Note 2, 'Liquidity and Going Concern,' that it has a history of and expects to continue to report negative cash flows from operations and a net loss, raising 'substantial doubt regarding the Company's ability to continue as a going concern.' This is further evidenced by a net loss of $9,894,762 for the nine months ended September 30, 2025, and net cash used in operating activities of $10,759,337 during the same period.

Analyst Insight

Investors should exercise extreme caution and consider avoiding CNSP stock due to the explicit 'going concern' warning and heavy reliance on dilutive equity financing. Only investors with a very high-risk tolerance and a deep understanding of early-stage pharmaceutical development should consider a position, acknowledging the significant risk of capital loss.

Financial Highlights

debt To Equity

N/A

revenue

N/A

operating Margin

N/A

total Assets

$ 11,869,258

total Debt

$ 1,959,117

net Income

$ -9,894,762

eps

$ -25.60

gross Margin

N/A

cash Position

$ 9,864,087

revenue Growth

N/A

Key Numbers

• $9.89M — Net Loss (Decreased by 15.3% from $11.68M year-over-year for the nine months ended September 30, 2025.)
• $9.86M — Cash and Cash Equivalents (Increased from $6.46M at December 31, 2024, primarily due to financing activities.)
• $13.54M — Proceeds from Equity Sales (Generated from the sale of common stock and warrants during the nine months ended September 30, 2025.)
• $10.76M — Net Cash Used in Operations (Reflects ongoing operational cash burn for the nine months ended September 30, 2025.)
• 1-for-12 — Reverse Stock Split Ratio (Effected on July 22, 2025, to adjust share structure.)
• 574,580 — Common Shares Outstanding (As of September 30, 2025, after multiple reverse stock splits.)
• $6.61M — Research and Development Expenses (Decreased from $7.79M year-over-year for the nine months ended September 30, 2025.)
• $3.39M — General and Administrative Expenses (Decreased from $3.91M year-over-year for the nine months ended September 30, 2025.)

Key Players & Entities

• CNS Pharmaceuticals, Inc. (company) — registrant
• A.G.P./Alliance Global Partners (company) — sales agent and placement agent
• NASDAQ Stock Market LLC (regulator) — exchange where common stock is registered
• $9,894,762 (dollar_amount) — net loss for nine months ended September 30, 2025
• $11,681,435 (dollar_amount) — net loss for nine months ended September 30, 2024
• $13,544,685 (dollar_amount) — proceeds from sale of common stock and warrants
• $9,864,087 (dollar_amount) — cash and cash equivalents as of September 30, 2025
• $10,759,337 (dollar_amount) — net cash used in operating activities for nine months ended September 30, 2025
• September 30, 2025 (date) — end of quarterly period
• July 22, 2025 (date) — date of 1-for-12 reverse stock split

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company's continued operations are subject to substantial doubt due to persistent net losses and negative cash flows from operations. Despite financing activities, the company has not achieved profitability, necessitating ongoing reliance on external funding.
• Dependence on Equity Financing [high — financial]: CNS Pharmaceuticals relies heavily on the sale of common stock and warrants to fund its operations, as evidenced by $13.54 million in proceeds from equity sales in the nine months ended September 30, 2025. This dependence creates vulnerability to market conditions and investor sentiment.
• High Research and Development Burn Rate [medium — operational]: Despite a reduction, R&D expenses remain significant at $6.61 million for the nine months ended September 30, 2025. Continued high R&D spending without commensurate revenue generation poses a substantial financial risk.
• Dilution from Equity Issuances [medium — financial]: The company has engaged in multiple equity sales and reverse stock splits to manage its share structure and raise capital. These actions can lead to significant dilution for existing shareholders, impacting the value of their holdings.
• Clinical Trial and Regulatory Approval Risks [high — regulatory]: As a pharmaceutical company, CNS Pharmaceuticals faces inherent risks associated with the lengthy, expensive, and uncertain process of clinical trials and obtaining regulatory approvals for its drug candidates. Failure to achieve these milestones can result in significant financial losses and delays.

Industry Context

CNS Pharmaceuticals operates in the highly competitive and capital-intensive biopharmaceutical industry, focusing on developing novel treatments for central nervous system diseases. This sector is characterized by long development cycles, high R&D costs, stringent regulatory hurdles, and significant risks associated with clinical trial success and market adoption. Companies often rely on substantial external financing to fund their operations until a product generates revenue.

Regulatory Implications

As a clinical-stage biopharmaceutical company, CNS Pharmaceuticals is subject to rigorous oversight by regulatory bodies like the FDA. The success of its drug candidates hinges on navigating complex clinical trial pathways and obtaining marketing approvals. Any delays, failures in trials, or adverse findings can have severe financial and operational consequences, impacting the company's ability to secure future funding and achieve its strategic objectives.

What Investors Should Do

1. Monitor cash burn rate and runway: Given the ongoing net losses and negative operating cash flow, investors should closely track the company's cash position and the rate at which it is being consumed to assess its ability to fund operations until profitability or further financing.
2. Evaluate R&D progress and clinical trial outcomes: The company's future value is heavily dependent on the success of its drug development pipeline. Investors should stay informed about clinical trial results and regulatory milestones.
3. Assess the impact of equity financing and dilution: Understand the terms and frequency of equity issuances, as these can significantly dilute existing shareholders' ownership and impact per-share metrics.
4. Consider the going concern disclosure: The explicit mention of substantial doubt about the company's ability to continue as a going concern is a critical risk factor that warrants careful consideration of the company's long-term viability.

Key Dates

• 2025-09-30: Nine months ended September 30, 2025 — Reporting period showing a reduced net loss of $9.89M compared to $11.68M in the prior year, driven by lower operating expenses.
• 2025-07-22: Reverse stock split — A 1-for-12 reverse stock split was executed to adjust the company's share structure, a common tactic for companies facing delisting concerns or seeking to improve per-share metrics.
• 2025-05-14: Public offering closing — Closing of a public offering that raised approximately $5 million in gross proceeds through the sale of common stock and warrants.
• 2025-05-13: Placement agency agreement — Agreement with A.G.P./Alliance Global Partners for a public offering of common stock and warrants.
• 2025-03-20: Increase in ATM sales agreement limit — The aggregate sales price for common shares under the AGP ATM Sales Agreement was increased to $43.5 million.
• 2024-07-30: Increase in ATM sales agreement limit — The aggregate sales price for common shares under the AGP ATM Sales Agreement was increased to $25.0 million.

Glossary

Accumulated deficit

The total cumulative net losses of a company since its inception, minus any cumulative net profits. It represents a deficit in equity. (Indicates the company has historically incurred more losses than profits, impacting its overall equity position.)

Additional paid-in capital

The amount of money a company receives from selling stock above its par value. It represents capital contributed by shareholders beyond the stated par value. (Shows significant capital raised from equity issuance, contributing to the company's equity but also reflecting dilution.)

Going concern

An accounting assumption that a business will continue to operate for the foreseeable future. If doubt exists, it must be disclosed. (The filing explicitly states substantial doubt about CNS Pharmaceuticals' ability to continue as a going concern, highlighting significant financial distress.)

Reverse stock split

A corporate action to reduce the number of outstanding shares of a company by consolidating existing shares into fewer, proportionally more valuable shares. (CNSP executed a 1-for-12 reverse stock split, indicating efforts to manage its share structure, potentially to meet exchange listing requirements or improve per-share metrics.)

Weighted average shares outstanding

The average number of a company's shares outstanding over a specific period, used to calculate earnings per share (EPS). (The significant increase in weighted average shares outstanding from 2024 to 2025 (e.g., 12,591 to 386,548 for nine months) reflects the impact of equity issuances and reverse stock splits on share count.)

Net cash used in operations

The amount of cash a company has spent on its core business operations during a period. A negative number indicates cash burn. (The company's ongoing negative cash flow from operations ($10.76M for nine months) underscores its reliance on financing to sustain operations.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, CNS Pharmaceuticals has reduced its net loss by 15.3% to $9.89 million, primarily due to decreased operating expenses in both general and administrative (down from $3.91M to $3.39M) and research and development (down from $7.79M to $6.61M). The company's cash position has strengthened significantly, rising to $9.86 million from $6.46 million, largely driven by substantial proceeds from equity sales. However, the company continues to operate with negative cash flow from operations and faces substantial doubt regarding its ability to continue as a going concern, a risk that persists despite operational improvements and financing activities.

Key Financial Figures

• $0.001 — he registrant's common stock, par value $0.001 per share, as of November 14, 2025 was
• $250,000 — xcess of the federally insured limit of $250,000. The amount in excess of the FDIC insur
• $5.2 million — initial aggregate sales price of up to $5.2 million. On July 30, 2024, the Company increase
• $25.0 million — ld under the AGP ATM Sales Agreement to $25.0 million (not including the original $5.2 millio
• $43.5 million — ld under the AGP ATM Sales Agreement to $43.5 million (which amount includes $6.4 million rem
• $6.4 million — to $43.5 million (which amount includes $6.4 million remaining from the $30.2 million set fo
• $30.2 million — ncludes $6.4 million remaining from the $30.2 million set forth above). On September 19, 2025
• $15.18 — and one accompanying Common Warrant was $15.18 and the combined purchase price of one
• $15.17 — and one accompanying Common Warrant was $15.17. Subject to certain ownership limitati
• $13.68 — of Common Stock at a price per share of $13.68 and expire five years from Initial Exer
• $68,600 — to receive annual cash compensation of $68,600. As of August 25, 2022, Dr. Waldemar Pr

Filing Documents

• cns_i10q-093025.htm (10-Q) — 464KB
• cns_ex3101.htm (EX-31.1) — 7KB
• cns_ex3102.htm (EX-31.2) — 7KB
• cns_ex3201.htm (EX-32.1) — 3KB
• cns_ex3202.htm (EX-32.2) — 3KB
• 0001683168-25-008466.txt ( ) — 2834KB
• cnsp-20250930.xsd (EX-101.SCH) — 20KB
• cnsp-20250930_cal.xml (EX-101.CAL) — 26KB
• cnsp-20250930_def.xml (EX-101.DEF) — 104KB
• cnsp-20250930_lab.xml (EX-101.LAB) — 249KB
• cnsp-20250930_pre.xml (EX-101.PRE) — 204KB
• cns_i10q-093025_htm.xml (XML) — 276KB

FINANCIAL INFORMATION

PART I FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements 3 Balance Sheets as of September 30, 2025 and December 31, 2024 (unaudited) 3 Statements of Operations for the three and nine months ended September 30, 2025 and 2024 (unaudited) 4 Statements of Stockholders' Equity (Deficit) for the three and nine months ended September 30, 2025 and 2024 (unaudited) 5 Statements of Cash Flows for the nine months ended September 30, 2025 and 2024 (unaudited) 6 Notes to the Financial Statements (unaudited) 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 14 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 20 Item 4.

Controls and Procedures

Controls and Procedures 20

OTHER INFORMATION

PART II OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 22 Item 1A.

Risk Factors

Risk Factors 22 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 23 Item 3. Defaults Upon Senior Securities 23 Item 4. Mine Safety Disclosures 23 Item 5. Other Information 23 Item 6. Exhibits 24

Signatures

Signatures 25 2

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION ITEM 1.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS CNS Pharmaceuticals, Inc. Balance Sheets (Unaudited) September 30, 2025 December 31, 2024 Assets Current Assets: Cash and cash equivalents $ 9,864,087 $ 6,461,378 Deferred offering costs 43,700 20,637 Subscription receivable – 882,539 Prepaid expenses and other current assets 1,483,948 1,293,954 Total current assets 11,391,735 8,658,508 Noncurrent Assets: Prepaid expenses, net of current portion 474,416 36,430 Property and equipment, net 3,107 6,005 Total noncurrent assets 477,523 42,435 Total Assets $ 11,869,258 $ 8,700,943 Liabilities and Stockholders' Equity (Deficit) Current Liabilities: Accounts payable and accrued expenses $ 1,928,324 $ 2,198,260 Notes payable 30,793 326,072 Total current liabilities 1,959,117 2,524,332 Total Liabilities 1,959,117 2,524,332 Stockholders' Equity (Deficit): Preferred stock, $ 0.001 par value, 416,667 shares authorized and 0 shares issued and outstanding – – Common stock, $ 0.001 par value, 25,000,000 shares authorized and 574,580 and 117,796 shares issued and outstanding, respectively 574 118 Additional paid-in capital 104,229,033 90,601,197 Accumulated deficit ( 94,319,466 ) ( 84,424,704 ) Total Stockholders' Equity (Deficit) 9,910,141 6,176,611 Total Liabilities and Stockholders' Equity (Deficit) $ 11,869,258 $ 8,700,943 See accompanying notes to the unaudited financial statements. 3 CNS Pharmaceuticals, Inc. Statements of Operations (Unaudited) Three Months Ended Three Months Ended Nine Months Ended Nine Months Ended September 30, 2025 September 30, 2024 September 30, 2025 September 30, 2024 Operating expenses: General and administrative $ 1,056,560 $ 1,383,913 $ 3,393,655 $ 3,909,928 Research and development 2,196,828 4,244,993 6,606,778 7,791,967 Total operating expenses 3,253,388 5,628,906 10,000,433 11,701,895 Loss from operations ( 3,253,388 ) ( 5,628,9

financial statements and footnotes

financial statements and footnotes. Common Stock On July 26, 2024, the Company entered into a Sales Agreement (the "AGP ATM Sales Agreement") with A.G.P./Alliance Global Partners ("AGP"). Pursuant to the terms of the AGP ATM Sales Agreement, the Company originally was permitted to sell from time to time through AGP, as sales agent or principal, shares of the Company's common stock, par value $0.001 per share with initial aggregate sales price of up to $5.2 million. On July 30, 2024, the Company increased the aggregate sales price of common shares that may be sold under the AGP ATM Sales Agreement to $25.0 million (not including the original $5.2 million). On March 20, 2025, the Company increased the aggregate sales price of common shares that may be sold under the AGP ATM Sales Agreement to $43.5 million (which amount includes $6.4 million remaining from the $30.2 million set forth above). On September 19, 2025, the Company decreased the sales price of common shares that may be sold under the AGP ATM Sales Agreement to $ 1.76 million, which amount does not include any shares of common stock sold prior to such date. During the nine months ended September 30, 2025, the Company has sold 127,582 shares of common stock pursuant to the AGP ATM Sales Agreement for net proceeds of approximately $ 9 million. As of September 30, 2025, the Company has sold 210,230 shares of common stock pursuant to the AGP ATM Sales Agreement for net proceeds of approximately $ 22.8 million. On May 13, 2025, the Company entered into a placement agency agreement (the "Placement Agency Agreement") with A.G.P./Alliance Global Partners (the "Placement Agent") for the public offering by the Company of (i) 27,084 shares of the Company's common stock, (ii) pre-funded warrants to purchase 302,295 shares of common stock (the "Pre-Funded Warrants"); and (iii) Series F Warrants to purchase up to an aggregate of 329,381 shares of common stock (the "Common Warrants"). The Common Warrants and Pre-Funded